Literature DB >> 23484893

A comparison of clinician-rated neuropsychological and self-rated cognitive assessments in patients with asthma and rheumatologic disorders.

Alan B Frol1, Aracely Vasquez, Yonatan Getahun, Maria Pacheco, David A Khan, E Sherwood Brown.   

Abstract

Although data are mixed, asthma and rheumatologic conditions may be associated with cognitive impairment. Medications may play a role because corticosteroids are associated with memory impairment. Therefore, an easily administered assessment of cognition would be useful in these patients. We assessed relationships between self-rated and clinician-rated cognitive performance and mood in patients with asthma and rheumatologic diseases. Participants included 31adults treated for asthma or rheumatologic disorders (17 receiving chronic prednisone therapy, and 14 not receiving prednisone). An objective assessment of a variety of cognitive domains was administered through clinician and patient-rated assessments of cognition. Composite scores for the objective (Global Clinical Rating [GCR]) and subjective (Neuropsychological Impairment Scale: Global Measure of Impairment [GMI]) measures of cognition were derived. Depression was assessed with the 17-item Hamilton Rating Scale for Depression (HRSD-17). A linear regression was conducted with GMI scores as dependent variable and GCR, HRSD-17 scores, and prednisone-use status, as independent variables. Significant differences between prednisone-treated patients and other patients were observed on the GCR, GMI, and HRSD-17. In the regression analysis, HRSD-17 scores, but not GCR scores, significantly predicted GMI scores. Prednisone-treated patients had higher levels of depressive symptoms and subjective and objective cognitive deficits than those not taking prednisone. In the combined patient groups, subjective cognitive assessment was more strongly related to depressive symptoms than objective cognition. Findings suggest physicians should be aware of the potential for cognitive deficits in patients taking corticosteroids and, when appropriate, should consider the use of objective neurocognitive tests or neuropsychology consultation to better characterize its presence and severity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23484893      PMCID: PMC3587715          DOI: 10.2500/aap.2013.34.3642

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  42 in total

Review 1.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

2.  Aging and response inhibition: Normative data for the Victoria Stroop Test.

Authors:  Angela K Troyer; Larry Leach; Esther Strauss
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2006-03

Review 3.  Neurobiological mechanisms in major depressive disorder.

Authors:  Marije aan het Rot; Sanjay J Mathew; Dennis S Charney
Journal:  CMAJ       Date:  2009-02-03       Impact factor: 8.262

4.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

Review 5.  Computerized cognitive assessment in primary care to identify patients with suspected cognitive impairment.

Authors:  Mary C Tierney; Miriam A Lermer
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 6.  Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy.

Authors:  E Sherwood Brown
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

7.  Randomized, placebo-controlled, crossover trial of memantine for cognitive changes with corticosteroid therapy.

Authors:  E Sherwood Brown; Miguel Vazquez; Alyson Nakamura
Journal:  Biol Psychiatry       Date:  2008-06-25       Impact factor: 13.382

8.  Attenuation of the effects of corticosteroids on declarative memory with lamotrigine.

Authors:  E Sherwood Brown; Justin Wolfshohl; Mujeeb U Shad; Miguel Vazquez; I Julian Osuji
Journal:  Neuropsychopharmacology       Date:  2007-11-14       Impact factor: 7.853

9.  Relationship of the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) to functional, emotional, and neuropsychological outcomes.

Authors:  Amanda O'Brien; Elizabeth Gaudino-Goering; Marla Shawaryn; Eugene Komaroff; Nancy B Moore; John DeLuca
Journal:  Arch Clin Neuropsychol       Date:  2007-09-11       Impact factor: 2.813

10.  Self-reported cognitive ability and global cognitive performance in adults with HIV.

Authors:  David E Vance; Lesley A Ross; Charles A Downs
Journal:  J Neurosci Nurs       Date:  2008-02       Impact factor: 1.230

View more
  4 in total

Review 1.  An excitatory synapse hypothesis of depression.

Authors:  Scott M Thompson; Angy J Kallarackal; Mark D Kvarta; Adam M Van Dyke; Tara A LeGates; Xiang Cai
Journal:  Trends Neurosci       Date:  2015-04-14       Impact factor: 13.837

Review 2.  Self-Reported Cognitive Function in Persons with Nonneurological Chronic Diseases: A Systematic Review.

Authors:  Heather Cuevas; Valerie Danesh; Ashley Henneghan
Journal:  J Aging Res       Date:  2022-03-31

Review 3.  Informed consent and biological agents in rheumatology and internal medicine.

Authors:  Gabriele Mandarelli; Florenzo Iannone; Stefano Ferracuti; Ignazio Grattagliano; Marcello Benevento; Biagio Solarino; Davide Ferorelli; Roberto Catanesi
Journal:  Eur J Clin Invest       Date:  2022-05-18       Impact factor: 5.722

Review 4.  Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.

Authors:  Mehala Subramaniapillai; Nicole E Carmona; Carola Rong; Roger S McIntyre
Journal:  Dialogues Clin Neurosci       Date:  2017-03       Impact factor: 5.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.